About US

Beijing, China







View Offices Request a Proposal

Evaluation & Assessment Review for New Drug R&D

2015 can be deemed as a big year for PHDS. We have been invited by oversea research organizations for 3 times to involve in the technical discussion and R&D evaluation for biological new drug development, like cellular immune anti-cancer drugs and gene recombinant coagulation factor. Our experts have evaluated and assessed the comprehensive R&D development progress and result, integrating the regulations and policies for new drug in China. Our clear opinion and definite suggestions made in analysis report have lead the R&D company through the Chinese regulatory and technical requirements, and have enhanced their regulatory capabilities to realize their product’s value better in China.